BPC-157 5mg research peptide
BPC-157 is a synthetic peptide of 15 amino acids. Its sequence is a partial fragment of a larger protein, named “body protection compound”, that was first isolated from gastric juice. Each vial contains 5mg of BPC-157 acetate as a lyophilised (freeze-dried) solid, ready for reconstitution under your laboratory’s own protocols.
Specification
| Catalogue number | BPC5-024 |
|---|---|
| Quantity per vial | 5mg |
| Sequence | H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH |
| Salt form | Acetate (1 × acetate) |
| Molecular formula | C62H98N16O22 · C2H4O2 (C64H102N16O24) |
| Molecular weight | 1479.6 g/mol (acetate salt); 1419.5 g/mol (free base) |
| Stated purity | 99% |
| Form | Lyophilised solid |
| Storage | -20°C, sealed, protected from light and moisture |
Where BPC-157 appears in the research literature
BPC-157 has been studied mainly in cell-culture and rodent models. Published work has looked at its interaction with growth-factor signalling, blood-vessel formation and the behaviour of cultured fibroblasts. These are preclinical findings only. BPC-157 is not an approved medicine, and nothing on this page suggests it is safe or effective for any use outside the laboratory.
Further reading: search PubMed for published studies on BPC-157.
Storage and handling
Keep the sealed vial frozen at -20°C, away from light and moisture, until you need it. Let the vial reach room temperature before opening to limit condensation. Your laboratory’s own procedures determine the choice of solvent, concentration and any further storage after reconstitution.
Related products
BPC-157 is listed in our specialist research peptides. Researchers often compare it with Thymosin Beta 4 (TB-500), which is in our thymic and immune peptides range. For reconstitution and storage, see our laboratory supplies, including 0.6% acetic acid and sterile 10ml vials.
For laboratory research use only. Not for human or veterinary use. Not a medicine, food, supplement or cosmetic.





Reviews
There are no reviews yet.